New PET tracer lights up pancreatic tumors in early trial
NCT ID NCT06129422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new imaging agent called NMK89 in 10 people with pancreatic cancer. NMK89 is designed to attach to a protein (MUC5AC) found on these cancer cells and show up on PET scans. The main goal was to check if it is safe and how well it helps doctors see the tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States